The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Fibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked Hypophosphatemia
Open accessAbstract
BACKGROUND: Mutations in fibroblast growth factor 23 (FGF-23) cause autosomal dominant hypophosphatemic rickets. Clinical and laboratory findings in this disorder are similar to those in oncogenic osteomalacia, in which tumors abundantly express FGF-23 messenger RNA, and to those in X-linked hypophosphatemia, which is caused by inactivating mutations in a phosphate-regulating endopeptidase called PHEX. Recombinant FGF-23 induces phosphaturia and hypophosphatemia in vivo, suggesting that it has a role in phosphate regulation. To determine whether FGF-23 circulates in healthy persons and whether it is elevated in those with oncogenic osteomalacia or X-linked hypophosphatemia, an immunometric assay was developed to measure it. METHODS: Using affinity-purified, polyclonal antibodies against [Tyr223]FGF-23(206-222)amide and [Tyr224]FGF-23(225-244)amide, we developed a two-site enzyme-linked immunosorbent assay that detects equivalently recombinant human FGF-23, the mutant form in which glutamine is substituted for arginine at position 179 (R179Q), and synthetic human FGF-23(207-244)amide. Plasma or serum samples from 147 healthy adults (mean [+/-SD] age, 48.4+/-19.6 years) and 26 healthy children (mean age, 10.9+/-5.5 years) and from 17 patients with oncogenic osteomalacia (mean age, 43.0+/-13.3 years) and 21 patients with X-linked hypophosphatemia (mean age, 34.9+/-17.2 years) were studied. RESULTS: Mean FGF-23 concentrations in the healthy adults and children were 55+/-50 and 69+/-36 reference units (RU) per milliliter, respectively. Four patients with oncogenic osteomalacia had concentrations ranging from 426 to 7970 RU per milliliter, which normalized after tumor resection. FGF-23 concentrations were 481+/-528 RU per milliliter in those with suspected oncogenic osteomalacia and 353+/-510 RU per milliliter (range, 31 to 2335) in those with X-linked hypophosphatemia. CONCLUSIONS: FGF-23 is readily detectable in the plasma or serum of healthy persons and can be markedly elevated in those with oncogenic osteomalacia or X-linked hypophosphatemia, suggesting that this growth factor has a role in phosphate homeostasis. FGF-23 measurements might improve the management of phosphate-wasting disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23
White, K. E., Evans, W. E., O'Riordan, J. L. H., Speer, M. C., Econs, M. J., Lorenz-Depiereux, B., Grabowski, M., Meitinger, T., & Strom, T. M. (2000) · Nature Genetics · doi:10.1038/81664 · Cited by 1,528
Self-citationCloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia
Shimada, T., Mizutani, S., Muto, T., Yoneya, T., Hino, R., Takeda, S., Takeuchi, Y., Fujita, T., Fukumoto, S., & Yamashita, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.101545198 · Cited by 1,457
Nussbaum, S. R., Zahradnik, R. J., Lavigne, J. R., Brennan, G. L., Nozawa-Ung, K., Kim, L. Y., Keutmann, H. T., Wang, C. A., Potts, J. T., & Segre, G. V. (1987) · Clinical Chemistry · doi:10.1093/clinchem/33.8.1364 · Cited by 808
Self-citationYamashita, T., Yoshioka, M., & Itoh, N. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3696 · Cited by 554
Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23
White, K. E., Carn, G., Lorenz-Depiereux, B., Benet-Pages, A., Strom, T. M., & Econs, M. J. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.00064.x · Cited by 493
Self-citationShimada, T. (2002) · Endocrinology · doi:10.1210/en.143.8.3179 · Cited by 446
FGF-23 Inhibits Renal Tubular Phosphate Transport and Is a PHEX Substrate
Bowe, A. E., Finnegan, R., Jan de Beur, S. M., Cho, J., Levine, M. A., Kumar, R., & Schiavi, S. C. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5084 · Cited by 344
White, K. E. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.2.497 · Cited by 329
Self-citationBai, X.-Y., Miao, D., Goltzman, D., & Karaplis, A. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210490200 · Cited by 276
Octreotide Therapy for Tumor-Induced Osteomalacia
Seufert, J., Ebert, K., Müller, J., Eulert, J., Hendrich, C., Werner, E., Schütze, N., Schulz, G., Kenn, W., Richtmann, H., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010839 · Cited by 234
Tumors Associated With Oncogenic Osteomalacia Express Genes Important in Bone and Mineral Metabolism
De Beur, S. M. J., Finnegan, R. B., Vassiliadis, J., Cook, B., Barberio, D., Estes, S., Manavalan, P., Petroziello, J., Madden, S. L., Cho, J. Y., et al. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.6.1102 · Cited by 212
Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets.
Holm, I. A., Huang, X., & Kunkel, L. M. (1997) · PubMed · Cited by 155
Oncogenic Osteomalacia Caused by a Phosphaturic Mesenchymal Tumor of the Oral Cavity
Yang, I. M., Park, Y. K., Hyun, Y. J., Kim, D. Y., Woo, J., Kim, S. W., Kim, J., Kim, Y. S., & Choi, Y. K. (1997) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.1997.12.1.89 · Cited by 27
Self-citation
Cited by
FGF23 induces left ventricular hypertrophy
Faul, C., Amaral, A. P., Oskouei, B., Hu, M.-C., Sloan, A., Isakova, T., Gutiérrez, O. M., Aguillon-Prada, R., Lincoln, J., Hare, J. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46122 · Cited by 2,027
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis
Shimada, T., Hasegawa, H., Yamazaki, Y., Muto, T., Hino, R., Takeuchi, Y., Fujita, T., Nakahara, K., Fukumoto, S., & Yamashita, T. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301264 · Cited by 1,883
Klotho converts canonical FGF receptor into a specific receptor for FGF23
Urakawa, I., Yamazaki, Y., Shimada, T., Iijima, K., Hasegawa, H., Okawa, K., Fujita, T., Fukumoto, S., & Yamashita, T. (2006) · Nature · doi:10.1038/nature05315 · Cited by 1,850
Fibroblast Growth Factor 23 and Mortality among Patients Undergoing Hemodialysis
Gutiérrez, O. M., Mannstadt, M., Isakova, T., Rauh-Hain, J. A., Tamez, H., Shah, A., Smith, K., Lee, H., Thadhani, R., Jüppner, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706130 · Cited by 1,727
Self-citation
Metadata
- Authors
- Jonsson, K. B., Zahradnik, R., Larsson, T., White, K. E., Sugimoto, T., Imanishi, Y., Yamamoto, T., Hampson, G., Koshiyama, H., Ljunggren, Ö., Oba, K., Yang, I. M., Miyauchi, A., Econs, M. J., Lavigne, J., & Jüppner, H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-04-24
- Volume
- 348
- Issue
- 17
- Pages
- 1656-1663
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2094262605
- Cited by
- 914
- References
- 13
- FWCI
- 29.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.